Mesoblast Limited (LWB) - Net Assets
Based on the latest financial reports, Mesoblast Limited (LWB) has net assets worth €597.44 Million EUR (≈ $698.47 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€784.68 Million ≈ $917.38 Million USD) and total liabilities (€187.24 Million ≈ $218.90 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Mesoblast Limited liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €597.44 Million |
| % of Total Assets | 76.14% |
| Annual Growth Rate | 0.94% |
| 5-Year Change | 2.76% |
| 10-Year Change | 13.12% |
| Growth Volatility | 11.86 |
Mesoblast Limited - Net Assets Trend (2014–2025)
This chart illustrates how Mesoblast Limited's net assets have evolved over time, based on quarterly financial data. Also explore Mesoblast Limited assets under control for the complete picture of this company's asset base.
Annual Net Assets for Mesoblast Limited (2014–2025)
The table below shows the annual net assets of Mesoblast Limited from 2014 to 2025. For live valuation and market cap data, see Mesoblast Limited stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | €597.44 Million ≈ $698.47 Million |
+24.38% |
| 2024-06-30 | €480.36 Million ≈ $561.59 Million |
-4.28% |
| 2023-06-30 | €501.84 Million ≈ $586.70 Million |
+0.96% |
| 2022-06-30 | €497.04 Million ≈ $581.10 Million |
-14.51% |
| 2021-06-30 | €581.40 Million ≈ $679.71 Million |
+5.84% |
| 2020-06-30 | €549.33 Million ≈ $642.22 Million |
+14.19% |
| 2019-06-30 | €481.05 Million ≈ $562.40 Million |
-11.90% |
| 2018-06-30 | €546.01 Million ≈ $638.34 Million |
+5.66% |
| 2017-06-30 | €516.77 Million ≈ $604.15 Million |
-2.16% |
| 2016-06-30 | €528.16 Million ≈ $617.48 Million |
+12.86% |
| 2015-06-30 | €467.99 Million ≈ $547.13 Million |
-13.20% |
| 2014-06-30 | €539.18 Million ≈ $630.36 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Mesoblast Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 84229357900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €1.61 Billion | 269.21% |
| Total Equity | €597.44 Million | 100.00% |
Mesoblast Limited Competitors by Market Cap
The table below lists competitors of Mesoblast Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Fsilon Furnishing and Construction Materials Corp
SHG:605318
|
$1.86 Billion |
|
Zhejiang Jingxin Pharmaceutical Co Ltd
SHE:002020
|
$1.86 Billion |
|
Ningbo Yongxin Optics Co Ltd
SHG:603297
|
$1.86 Billion |
|
Sarepta Therapeutics Inc
NASDAQ:SRPT
|
$1.86 Billion |
|
Harbin Hatou Investment Co Ltd
SHG:600864
|
$1.86 Billion |
|
SIRIUS REAL ESTATE LTD.
F:EYI
|
$1.86 Billion |
|
Zotye Automobile Co Ltd
SHE:000980
|
$1.86 Billion |
|
Streamax Technology Co Ltd
SHE:002970
|
$1.86 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mesoblast Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 480,355,000 to 597,442,000, a change of 117,087,000 (24.4%).
- Net loss of 102,142,000 reduced equity.
- New share issuances of 161,205,000 increased equity.
- Other factors increased equity by 58,024,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-102.14 Million | -17.1% |
| Share Issuances | €161.21 Million | +26.98% |
| Other Changes | €58.02 Million | +9.71% |
| Total Change | €- | 24.38% |
Book Value vs Market Value Analysis
This analysis compares Mesoblast Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.74x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.06x to 2.74x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-06-30 | €1.20 | €1.28 | x |
| 2018-06-30 | €1.14 | €1.28 | x |
| 2019-06-30 | €0.97 | €1.28 | x |
| 2020-06-30 | €0.95 | €1.28 | x |
| 2021-06-30 | €0.90 | €1.28 | x |
| 2022-06-30 | €0.76 | €1.28 | x |
| 2023-06-30 | €0.62 | €1.28 | x |
| 2024-06-30 | €0.42 | €1.28 | x |
| 2025-06-30 | €0.47 | €1.28 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mesoblast Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -17.10%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -593.92%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 1.31x
- Recent ROE (-17.10%) is below the historical average (-14.72%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -14.01% | -322.93% | 0.03x | 1.57x | €-129.45 Million |
| 2015 | -20.57% | -487.04% | 0.03x | 1.67x | €-143.04 Million |
| 2016 | -0.78% | -9.70% | 0.06x | 1.30x | €-56.94 Million |
| 2017 | -14.86% | -3184.70% | 0.00x | 1.27x | €-128.49 Million |
| 2018 | -6.46% | -203.51% | 0.03x | 1.27x | €-89.89 Million |
| 2019 | -18.67% | -537.01% | 0.03x | 1.36x | €-137.90 Million |
| 2020 | -14.19% | -242.38% | 0.04x | 1.34x | €-132.87 Million |
| 2021 | -17.00% | -1325.25% | 0.01x | 1.28x | €-156.95 Million |
| 2022 | -18.38% | -894.59% | 0.02x | 1.33x | €-141.05 Million |
| 2023 | -16.32% | -1091.71% | 0.01x | 1.33x | €-132.07 Million |
| 2024 | -18.31% | -1490.27% | 0.01x | 1.39x | €-135.99 Million |
| 2025 | -17.10% | -593.92% | 0.02x | 1.31x | €-161.89 Million |
Industry Comparison
This section compares Mesoblast Limited's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $698,488,333
- Average return on equity (ROE) among peers: -63.13%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mesoblast Limited (LWB) | €597.44 Million | -14.01% | 0.31x | $1.86 Billion |
| TIZIANA LIFE SCIENCES LTD (0RP) | $5.54 Million | -319.56% | 1.20x | $157.03 Million |
| Theravance Biopharma Inc (0TB) | $441.80 Million | 197.40% | 0.37x | $828.57 Million |
| PreveCeutical Medical Inc (18H) | $-4.10 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $538.39 Million | -12.38% | 0.07x | $44.01 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $32.50 Million | -376.16% | 5.37x | $1.12 Billion |
| ZAI LAB LTD0000006 (1ZLB) | $1.38 Billion | -51.05% | 0.17x | $2.05 Billion |
| BioNTech SE (22UA) | $493.49 Million | -36.28% | 0.62x | $23.24 Billion |
| Ascletis Pharma Inc (2VJ) | $2.54 Billion | -12.40% | 0.05x | $2.05 Billion |
| ALPHAMAB ONCOLO.DL-000002 (3NK) | $1.56 Billion | -20.91% | 0.36x | $978.26 Million |
| BIOMIND LABS INC. (3XI) | $-247.66K | 0.00% | 0.00x | $3.31 Million |
About Mesoblast Limited
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic… Read more